Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion

Fig. 1

BCL-2 expression in chronic lymphocytic leukemia (CLL) and normal control (NC) T cells. (a) Flow cytometry gating strategy used for defining immune cell subsets. Representative examples of the difference in BCL-2 expression in CD3+ T, CD4+ T, and CD8+ T cells in NC and patients with CLL. (b–d) Percentages and MFI of cells positive for intracellular BCL-2 expression in CD3+ T (b, n = 266), CD4+ T (c, n = 110), and CD8+ T (d, n = 110) cells between NC and CLL. (e) Comparison charts generated by Cytobank on BCL-2 expression in 10 cases each of NC and CLL. Differences are shown using scatter plots (***p < 0.001, ****p < 0.0001)

Back to article page

Molecular Cancer

ISSN: 1476-4598